Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

RxSight Inc has demonstrated significant financial strength, evidenced by a gross margin of 71.6%, which increased by 980 basis points year-over-year, surpassing market expectations. The company's revenue from Light Adjustable Lenses (LAL) totaled $28.5 million, marking a robust 60% growth and aligning with consensus estimates, while the revenue from Light Delivery Devices (LDD) remained stable at $10.7 million with a 7% increase. Furthermore, the rising utilization rate of LALs per installed LDD, now at 10.9 from 10.2 in the previous quarter, indicates strong operational momentum that supports the potential for sustained double-digit growth.

Bears say

RxSight Inc. has reported a significant deceleration in the utilization growth of its Light Adjustable Lenses (LAL), which dropped to 9% year-over-year in the fourth quarter of 2024, compared to growth rates between 17% to 22% in the preceding five quarters. The company is facing challenges in the U.S. intraocular lens (IOL) market, where utilization has potentially stagnated, compounded by adverse conditions in the broader cataract surgery market, impacting overall sales performance. Furthermore, the company's financial outlook is concerning as analysts have lowered their earnings per share estimates for 2025 and 2026, citing risks related to market competition, limited adoption of their technology due to additional capital requirements, and the possibility of dilutive financing challenges.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Buy based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.